Begré, Lorin; Boyd, Anders; Plissonnier, Marie-Laure; Testoni, Barbara; Salazar-Vizcaya, Luisa; Suter-Riniker, Franziska; Scholtès, Caroline; Béguelin, Charles; Rockstroh, Jürgen K; Günthard, Huldrych F; Calmy, Alexandra; Cavassini, Matthias; Hirsch, Hans H; Schmid, Patrick; Bernasconi, Enos; Levrero, Massimo; Wandeler, Gilles; Zoulim, Fabien; Rauch, Andri (2024). Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy. (In Press). The journal of infectious diseases Oxford University Press 10.1093/infdis/jiae189
|
Text
jiae189.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (782kB) | Preview |
BACKGROUND
We evaluated long-term trajectories of circulating hepatitis B virus (HBV)-RNA and hepatitis B core-related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study.
METHODS
We included 29 persons with HIV (PWH) with HBsAg loss and 29 matched PWH without loss. We compared HBV-RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV-RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates.
RESULTS
HBsAg loss occurred after a median of 4 years (IQR 1 - 8). All participants with HBsAg loss achieved suppressed HBV-DNA and undetectable HBV-RNA preceding undetectable qHBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of the participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After two years on tenofovir, an HBV RNA decline ≥1 log10 copies/ml had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/ml had 91.0% sensitivity and 64.5% specificity.
CONCLUSIONS
HBV-RNA suppression preceded undetectable qHBsAg levels, and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in PWH. HBcrAg remained detectable in approximately 20% of persons with, and 50% of persons without HBsAg loss.
Actions (login required)
 |
Edit item |